Abstract:Cancer treatments, particularly for solid tumors like neuroblastoma, often entail severe side effects, resistance, and the potential for secondary malignancies. To address these challenges, we explored an innovative approach employing tumor-targeting peptides. Recently, we unveiled the tumor evolution regulatory role of retinal-degeneration protein-3 (RD3) in therapy defying progressive tumors. Here in we investigated the therapeutic potential of RD3 peptides. Utilizing neuroblastoma, the most common cancer at infancy, as the tumor model, we investigated the delivery and therapeutic potential RD3 peptide. Five peptides representing unique regions, each with a C-terminal TAT tag for fluorescence and an N-terminal amide cap were developed. Peptide homing capabilities (Cell Tracking aasay) and relative potential in modifying metastatic state including invasion (Matrigel invasion assay), migration (scratch-wound assay), clonal expansion (LDTA) and tumorosphere formation (LDTA) was investigated utilizing patient derived clinical therapy defied progressive NB cells NB-EBc1 from adrenal mass and SK-N-FI from bone marrow. Whole genome RNA sequencing was performed using novogene (Illumina) platform. All peptides screened displayed tumor cell internalization and inflicted cell death at varying degrees. Among the five peptides investigated, two peptides (RD3 Pep-1 and RD3 Pep-3) profoundly inhibited cell proliferation, migration, invasion, and tumorosphere formation. A novel molecular targeted oncolytic peptide, validated through RNA sequencing, demonstrates promising efficacy for treating therapy-resistant progressive neuroblastoma. These outcomes uniquely highlight the therapeutic potential of RD3 peptides, offering a novel therapeutic candidate to counter therapy defying progressive disease. Further, the results defined the synergistic benefit RD3 peptide deliver with the current clinical maintenance therapy (GD2 immunotherapy for neuroblastoma). Together, these results identified a molecular targeted novel oncolytic peptide that could complement current standards of maintenance therapy for therapy defying progressive disease. Funding: This work was partially or in full, funded by Oklahoma Center for the Advancement of Science and Technology, OCAST-HR19-04; National Institutes of Health, NIH-P20GM103639 and; NIH-NCI- Cancer Center Support Grant P30CA225520 and Department of Defense DoD-CA210339. Citation Format: Dinesh Babu Somasundaram, Poorvi Subramanian, Sreenidhi Mohanvelu, Sheeja Aravindan, Natarajan Aravindan. Novel molecular targeted tumor targeted oncolytic peptide for the treatment of therapy resistant progressive neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB221.

Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma

Neuropilin-2–Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma

Neuropilin-2 is Involved in Tumor Growth and Angiogenesis of Pancreatic Adenocarcinoma

Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver

Data from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis

TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma

Abstract A105: Pharmacological inhibition of nicotinamide adenine dinucleotide (NAD+) production enzyme nicotinamide phosphoribosyltransferase (NAMPT) impairs cellular survival, energy metabolism, and tumor growth in neuroblastoma (NB) models

The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice

A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization

NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma

Abstract LB221: Novel molecular targeted tumor targeted oncolytic peptide for the treatment of therapy resistant progressive neuroblastoma

Effect of Antiangiogenic Therapy on Slowly Growing, Poorly Vascularized Tumors in Mice

Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer

DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

5UTR translational inhibition of neuroblastoma dependency factors using the CR-1-31-B rocaglate

Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2

Novel Src/Abl Tyrosine Kinase Inhibitor Bosutinib Suppresses Neuroblastoma Growth Via Inhibiting Src/Abl Signaling

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma